HOME >> MEDICINE >> NEWS
Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center

It is a drug suffused in promise, a next-generation therapy that has shown glimmers of powerful potential. Iressa is the kind of treatment that oncologists dream of - a pill that can be swallowed once a day, a non-toxic therapy that causes few side effects. For 10 percent of patients who have tried it, people who have no other options left for them, Iressa seems to make the difference between life and death. Another 30 percent to 40 percent of patients who have used the drug have a better, if not a longer, life.

But for most patients, Iressa does not shrink their cancer. That fact has become a challenge to researchers at The University of Texas M. D. Anderson Cancer Center. They are dedicated to solving the central puzzle that Iressa, and similar other targeted therapies, pose - what are the cancers that may best respond, and which patients will benefit?

M. D. Anderson researchers have been at the forefront of testing Iressa, as well as a slew of other experimental drugs that target critical cancer cell pathways. They have been involved in all phases of clinical trials looking at the effectiveness of Iressa in common lung cancer, work that helped lead to federal Food and Drug Administration approval of the drug in early 2003 for use when standard therapy has not helped lung cancer patients.

Now, investigators at M. D. Anderson are testing Iressa in malignant brain cancer and are poised to study it in a number of cancers, including head and neck, breast, and prostate, along with further investigations in lung cancer.

"M. D. Anderson is one of the leading institutions in developing targeted therapies such as Iressa," says Frank Fossella, M.D., professor in the Department of Thoracic/Head and Neck Medical Oncology, who has treated many lung and other head and neck cancers where it has shown tantalizing benefit.

"So far, Iressa has been a good news, bad news story. The response rates are not as high as we woul
'"/>

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center
28-Apr-2004


Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Gene mutations predict which lung cancers will respond to Iressa
2. Iressa news backgrounder
3. Chemoprevention backgrounder: Working for a future of cancer chemoprevention
4. Cancer gene therapy news backgrounder: New ideas fuel next generation gene therapy research
5. Cancer markers news backgrounder: Future of cancer diagnosis, treatment lies in tumor barcode
6. St. Jude scientist to lead NCI Pediatric Preclinical Testing Program
7. Testing drugs ability to reverse stroke after standard three-hour window has closed
8. Testing may one day pinpoint which early-stage cancer patients are at risk for relapse
9. Testing earlier for gestational diabetes a smarter way to screen pregnant women
10. Testing for alcohol problems in the workplace
11. UNC Researchers Testing First In New Class Of AIDS Drugs

Post Your Comments:
(Date:4/1/2015)... (PRWEB) April 01, 2015 Pricing Healthcare ... last several months, bring coverage to a third of all ... states of Massachusetts, Kansas, and Iowa, and the first dedicated eye ... center in Dallas, TX was also added. , In addition, the ... to and general interest in the platform continue to grow across ...
(Date:4/1/2015)... With so much wet weather over the past ... their time indoors. When all this time is spent inside, ... latest article from Clean Crawls offers excellent advice to ... , One of the ways to improve the air ... The article states that, “Toluene, Xylene, and Benzene are all ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 "Giving credit ... to form. Its rewards are inestimable." - Loretta Young ... individuals in the water resources profession. The Call ... Please consider nominating yourself, a colleague, or organization for ... 2015. Learn more about the AWRA Awards and view ...
(Date:4/1/2015)... Decora Preset 30 Minute Countdown Timer, a ... Hardware City.’ The product helps in automatically switching off any ... the related electronic device is automatically turned off after the ... said, “We are glad that this amazing product is now ... Timer Switch in just a few clicks. The product has ...
(Date:4/1/2015)... TCS Healthcare Technologies (TCS), a leading provider ... and population health arenas, is pleased to announce a ... is fully integrated with the ACUITY platform. , The ... ET, will be led by Jeff Frater, RN, BSN, ... the feature-rich portal as well as the importance of ...
Breaking Medicine News(10 mins):Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 2Health News:PricingHealthcare.com Adds Facilities in 5 States, Hits 10,000 Monthly Users Milestone 3Health News:3 Simple Ways to Improve Home Air Quality Listed by Clean Crawls in Latest Article 2Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 2Health News:Nominations Sought for National Water Resources Awards and Student Scholarships 3Health News:Leviton Decora Preset 30 Minute Countdown Timer Available On TheHardwareCity.com 2Health News:TCS Healthcare Technologies Releases Acuity Connect 2Health News:TCS Healthcare Technologies Releases Acuity Connect 3
(Date:4/1/2015)... 1, 2015  Galmed Pharmaceuticals Ltd. (Nasdaq: ... on the development and commercialization of a once-daily, ... and cholesterol gallstones, today announced that it has ... of Clinical Operations. Mr. Tonelli brings ... development and regulatory affairs.  From 2005 to 2014, ...
(Date:4/1/2015)... -- Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... office-based dental, animal health and medical practitioners, announced today ... company GmbH.  scil animal care is a highly specialized ... and services to veterinarians primarily in North ... on January 19, 2015. scil animal care ...
(Date:3/31/2015)... , March 31, 2015 Neurocrine Biosciences, Inc. ... entered into an exclusive collaboration and licensing agreement for ... in Japan and other select ... Mitsubishi Tanabe intends to initially develop NBI-98854 in ... Huntington,s disease and tardive dyskinesia. Neurocrine retains full commercial ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 2Galmed Pharmaceuticals Announces the Appointment of George Tonelli as Vice President of Clinical Operations 3Henry Schein Completes Acquisition of scil animal care 2Henry Schein Completes Acquisition of scil animal care 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 2Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 3Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets 4
Cached News: